Lembaz is now
FDA approved
1,2

Lembaz is indicated to reduce the risk of mortality in adult and pediatric patients, who weigh 7 kg or greater, with Niemann-Pick disease type C (NPC) with neurological manifestations that started at less than 6 years of age.1,2

Woodrow, a real patient receiving Lembaz since 20 months old, diagnosed with I-NPC at 3 months old. Individual results may vary.

I-NPC=infantile-onset NPC.

Peer support for patients

The Caregiver Ambassador Program connects your patients’ caregivers with others who have navigated I-NPC and treatment with Lembaz.

Accessing Lembaz starts here

The following forms and guides are intended for healthcare professionals and office staff to help patients access Lembaz.

Patient Enrollment Form

Completed by healthcare professionals to order Lembaz and enroll patients in LembazTM Family Support

Letter of Medical Necessity Template

Template for healthcare professionals to support coverage requests by documenting a patient’s medical need for Lembaz

Prior Authorization Checklist

A checklist for healthcare professionals to help prepare and submit prior authorization documentation for Lembaz

Billing and Coding Guide

Billing and coding information for healthcare professionals to help support patient access to Lembaz

Dosing and Administration Guide

Information about Lembaz dosing, administration, and monitoring

Emmy, a real patient receiving Lembaz since 2.5 years old, diagnosed with I-NPC at 8 months old, and her mom. Individual results may vary.

Stay connected

Sign up to receive information about Lembaz and how you can best support your patients living with I-NPC.

Have questions about Lembaz?

Connect with a Lembaz Key Account Manager (KAM) for product, treatment, or access support.